Table 2:

Univariate analysis of patients’ baseline characteristics in cohorts with iodine staining without and with ICH (n = 95)

Patient Characteristics	No Hemorrhage (n = 58)	Hemorrhage (n = 37)	P Value
Age (mean) (SD) (yr)	68 (12.1)	67.7 (11.6)	.897^{^a}
Male sex (No.) (%)	28 (48.3%)	19 (51.3%)	.770^{^b}
History of hypertension (No.) (%)	28 (48.3%)	18 (48.6%)	.972^{^b}
History of diabetes mellitus (No.) (%)	13 (22.4%)	17 (45.9%)	.016^{^b}
History of atrial fibrillation (No.) (%)	28 (48.3%)	12 (32.4%)	.105^{^b}
MT duration (median) (IQR) (min)	70 (55–95)	60 (46–90)	.310^{^c}
Time of symptom onset to puncture (median) (IQR) (min)	200 (144–313)	230 (178–343)	.169^{^c}
ASPECTS (median) (IQR)	8 (7–9)	8 (7–9)	.348^{^c}
Baseline NIHSS (mean) (SD)	16 (6)	19 (7)	.067^{^a}
rLMC (mean) (SD)	11.8 (4.3)	9.4 (4.6)	.01^{^a}
Platelet count (median) (IQR) (10⁹/L)	133.8 (96.7–175.4)	130 (100.3–167.9)	.694^{^c}
hs-CRP (median) (IQR) (mg I/L)	8.4 (1.2–45.3)	6.9 (0.5–41.2)	.904^{^c}
Occlusion site
ICA occlusion (No.) (%)	15 (25%)	13 (31.5%	.334^{^b}
M1 trunk occlusion (No.) (%)	30 (51.7%)	18 (48.6%)	.770^{^b}
M2 trunk occlusion (No.) (%)	13 (22.4%)	6 (16.2%)	.461^{^b}
Thrombectomy devices
Solitaire^{^d}	13 (22.4%)	8 (21.6%)	.983^{^b}
Sofia^{^e}+Aperio^{^f}	13 (22.4%)	10 (27%)	.609^{^b}
Aperio	20 (34.5%)	14 (37.8%)	.739^{^b}
Sofia	12 (20.7%)	5 (13.5%)	.374^{^b}
Attempts of aspiration or stent retriever (median) (IQR)	1 (1–1)	1 (1-1)	.840^{^c}
Antiplatelet therapy (No.) (%)	39 (67.2)	25 (67.6)	.974^{^b}
Thrombolytic therapy (No.) (%)	12 (20.7)	7 (18.9)	.833^{^b}
Anticoagulant therapy (No.) (%)	12 (20.7)	6 (16.2)	.587^{^b}
Statin treatment (No.) (%)	29 (50)	24 (64.9)	.155^{^b}

Note:—rLMC indicates regional leptomeningeal collateral score; hs-CRP, hypersensitive c-reactive protein.
↵a One-way ANOVA.
↵b Pearson χ² test.
↵c Mann-Whitney test.
↵d Covidien.
↵e Microvention.
↵f Acandis.